Research graph
References from In vivo CAR-T cell generation: a production-rate framework linking vector and cellular pharmacology. Local targets link to admitted publications; unresolved targets remain external evidence.
CAR-T cell therapy: current limitations and potential strategies
10.1038/s41408-021-00459-7 · 2021 · External reference
Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments
10.1007/s11899-021-00635-3 · 2021 · External reference
CAR-T cell manufacturing landscape—lessons from the past decade and considerations for early clinical development
10.1016/j.omtm.2024.101250 · 2024 · External reference
In vivo CAR-T therapies-a new era of programmable immunity
10.3390/ijms27041737 · 2026 · External reference
CAR-T cells in solid tumors: challenges and breakthroughs
10.1016/j.xcrm.2025.102353 · 2025 · External reference
In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies
10.1186/s40164-025-00725-5 · 2025 · External reference
Current state of CAR-T cell therapies for solid tumors
10.1016/j.medj.2026.101028 · 2026 · External reference
Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion
10.1016/j.ebiom.2022.103941 · 2022 · External reference
CAR T cells produced in vivo to treat cardiac injury
10.1126/science.abm0594 · 2022 · External reference
In vivo CAR T cell generation to treat cancer and autoimmune disease
10.1126/science.ads8473 · 2025 · External reference
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
10.1016/s0140-6736(25)01030-x · 2025 · External reference
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
10.1038/s41591-026-04244-6 · 2026 · External reference
Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010
10.1182/blood-2025-lba-1 · 2025 · External reference
In vivo site-specific engineering to reprogram T cells
10.1038/s41586-026-10235-x · 2026 · External reference
Optimizing In vivo CAR-T cell engineering for cancer immunotherapy
10.1158/0008-5472.can-25-3748 · 2026 · External reference
Clinical technology advances driving in vivo CAR therapy
10.1016/j.tibtech.2025.11.006 · 2026 · External reference
In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges
10.1016/j.bict.2025.100027 · 2026 · External reference
In vivo CAR engineering for immunotherapy
10.1038/s41577-025-01174-1 · 2025 · External reference
Direct in vivo CAR T cell engineering
10.1016/j.tips.2024.03.004 · 2024 · External reference
Regulatory framework for advanced therapy medicinal products in Europe and United States
10.3389/fphar.2019.00921 · 2019 · External reference
Best practices and considerations for clinical pharmacology and pharmacometric aspects for optimal development of CAR-T and TCR-T cell therapies: an industry perspective
10.1002/cpt.2986 · 2023 · External reference
Long term follow-up after administration of human gene therapy products: guidance for industry
2020 · External reference
Cytokine control of memory T-cell development and survival
10.1038/nri1052 · 2003 · External reference
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
10.1084/jem.20050732 · 2005 · External reference
Molecular and cellular insights into T cell exhaustion
10.1038/nri3862 · 2015 · External reference
Chromatin states define tumour-specific T cell dysfunction and reprogramming
10.1038/nature22367 · 2017 · External reference
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
10.1038/s41586-019-1325-x · 2019 · External reference
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
10.1038/s41586-019-1326-9 · 2019 · External reference
TOX is a critical regulator of tumour-specific T cell differentiation
10.1038/s41586-019-1324-y · 2019 · External reference
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells
10.1158/2326-6066.cir-14-0186 · 2015 · External reference
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
10.1038/nm.3838 · 2015 · External reference
Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent
10.1016/j.celrep.2017.09.015 · 2017 · External reference
In vivo engineering of CAR-T cells: delivery strategies and clinical translation
10.1186/s40364-026-00899-y · 2026 · External reference
Lipid nanoparticles for mRNA delivery
10.1038/s41578-021-00358-0 · 2021 · External reference
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
10.1038/s41578-022-00529-7 · 2023 · External reference
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
10.1136/jitc-2022-006292 · 2023 · External reference
In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand
10.1182/blood.2024024523 · 2024 · External reference
Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy
10.1186/s12943-025-02515-3 · 2026 · External reference
Engineering the next generation of CAR T-cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance
10.3389/fonc.2025.1698442 · 2026 · External reference
Advancing CAR T-cell therapy in solid tumors: current landscape and future directions
10.3390/cancers17172898 · 2025 · External reference
Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors
10.3389/fonc.2025.1652329 · 2025 · External reference
CAR-T cells: the long and winding road to solid tumors
10.1038/s41419-018-0278-6 · 2018 · External reference
Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy
10.1007/s00262-025-04278-8 · 2026 · External reference
T cell immunotherapy for solid tumors: limitations, progress, and future prospects
10.3389/fimmu.2026.1755751 · 2026 · External reference
Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors
10.1038/s43018-021-00244-2 · 2021 · External reference
Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment
10.3389/fimmu.2025.1643941 · 2025 · External reference
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment
10.1186/s40164-024-00564-w · 2024 · External reference
An evolved AAV variant enables efficient genetic engineering of murine T cells
10.1016/j.cell.2022.12.022 · 2023 · External reference
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
10.1016/j.it.2004.12.003 · 2005 · External reference
Dendritic cells and their role in immunotherapy
10.3389/fimmu.2020.00924 · 2020 · External reference
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
10.1038/s41577-020-00490-y · 2021 · External reference
The pharmacology of second-generation chimeric antigen receptors
10.1038/nrd4597 · 2015 · External reference
Rapid manufacturing of non-activated potent CAR T cells
10.1038/s41551-021-00842-6 · 2022 · External reference
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
10.1182/blood-2012-05-431718 · 2013 · External reference
A human memory T cell subset with stem cell-like properties
10.1038/nm.2446 · 2011 · External reference
Prevalence of serum IgG and neutralizing factors against AAV types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors
10.1089/hum.2009.182 · 2010 · External reference
CD8(+) T-cell responses to adeno-associated virus capsid in humans
10.1038/nm1549 · 2007 · External reference
AAV vector immunogenicity in humans: a long journey to successful gene transfer
10.1016/j.ymthe.2019.12.010 · 2020 · External reference
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
10.1038/nnano.2017.57 · 2017 · External reference
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
10.1038/s41467-020-19486-2 · 2020 · External reference
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing
10.1038/s41565-020-0669-6 · 2020 · External reference
Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy
10.1038/s41392-025-02512-4 · 2025 · External reference
A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells
10.1126/sciadv.abf1333 · 2021 · External reference
Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with Sleeping Beauty transposon for the treatment of acute lymphoblastic leukemia
10.1089/hum.2017.207 · 2018 · External reference
T cell-specific non-viral DNA delivery and in vivo CAR generation using targeted lipid nanoparticles
10.1136/jitc-2025-011759 · 2025 · External reference
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia
10.1038/s41408-021-00508-1 · 2021 · External reference
In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313
10.1016/j.immuni.2025.01.009 · 2025 · External reference
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
10.1038/nature21405 · 2017 · External reference
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
10.1038/s41591-022-02017-5 · 2022 · External reference
An inducible caspase 9 safety switch for T-cell therapy
10.1182/blood-2004-11-4564 · 2005 · External reference
Inducible apoptosis as a safety switch for adoptive cell therapy
10.1056/nejmoa1106152 · 2011 · External reference
Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
10.1038/s41577-022-00825-x · 2023 · External reference
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
10.1182/blood-2017-06-786129 · 2017 · External reference
Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor–T cells
10.1002/psp4.12388 · 2019 · External reference
Quantitative systems pharmacology model of chimeric antigen receptor T-cell therapy
10.1111/cts.12636 · 2019 · External reference
Treatment with living drugs: Pharmaceutical aspects of CAR T cells
10.1159/000525052 · 2022 · External reference
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics
10.1038/s41540-024-00355-3 · 2024 · External reference
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
10.1182/bloodadvances.2020002394 · 2020 · External reference
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
10.1182/blood-2017-06-793141 · 2017 · External reference
Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology
10.1016/j.addr.2022.114421 · 2022 · External reference
Eliminating REMS for CAR T-Cell Therapies: An opportunity to improve access
10.3390/cancers17193216 · 2025 · External reference
FDA experience on CAR T cell pharmacokinetics/pharmacodynamics and model-based assessments
10.1002/cpt.3703 · 2025 · External reference
Considerations for the development of chimeric antigen receptor (CAR) T cell products: guidance for industry
2024 · External reference
First-in-human in vivo CAR T-cell generation using a CD8-targeted lipid nanoparticle platform in relapsed/refractory B-cell lymphoma
10.1200/jco.2026.44.16_suppl.7014 · 2026 · External reference
In situ generation of EBNA1 CAR-T cells eradicates antigen specific auto-immune B cells for multiple sclerosis treatment
10.1016/j.apsb.2026.03.033 · 2026 · External reference
Best practices and considerations for clinical pharmacology and pharmacometric aspects for optimal development of CAR-T and TCR-T cell therapies: an industry perspective
10.1002/cpt.2986 · ExternalCitation · doi-reference
FDA experience on CAR T cell pharmacokinetics/pharmacodynamics and model-based assessments
10.1002/cpt.3703 · ExternalCitation · doi-reference
Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor–T cells
10.1002/psp4.12388 · ExternalCitation · doi-reference
Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy
10.1007/s00262-025-04278-8 · ExternalCitation · doi-reference
Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments
10.1007/s11899-021-00635-3 · ExternalCitation · doi-reference
Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology
10.1016/j.addr.2022.114421 · ExternalCitation · doi-reference
In situ generation of EBNA1 CAR-T cells eradicates antigen specific auto-immune B cells for multiple sclerosis treatment
10.1016/j.apsb.2026.03.033 · ExternalCitation · doi-reference
In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges
10.1016/j.bict.2025.100027 · ExternalCitation · doi-reference
An evolved AAV variant enables efficient genetic engineering of murine T cells
10.1016/j.cell.2022.12.022 · ExternalCitation · doi-reference
Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent
10.1016/j.celrep.2017.09.015 · ExternalCitation · doi-reference
Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion
10.1016/j.ebiom.2022.103941 · ExternalCitation · doi-reference
In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313
10.1016/j.immuni.2025.01.009 · ExternalCitation · doi-reference
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
10.1016/j.it.2004.12.003 · ExternalCitation · doi-reference
Current state of CAR-T cell therapies for solid tumors
10.1016/j.medj.2026.101028 · ExternalCitation · doi-reference
CAR-T cell manufacturing landscape—lessons from the past decade and considerations for early clinical development
10.1016/j.omtm.2024.101250 · ExternalCitation · doi-reference
Clinical technology advances driving in vivo CAR therapy
10.1016/j.tibtech.2025.11.006 · ExternalCitation · doi-reference
Direct in vivo CAR T cell engineering
10.1016/j.tips.2024.03.004 · ExternalCitation · doi-reference
CAR-T cells in solid tumors: challenges and breakthroughs
10.1016/j.xcrm.2025.102353 · ExternalCitation · doi-reference
AAV vector immunogenicity in humans: a long journey to successful gene transfer
10.1016/j.ymthe.2019.12.010 · ExternalCitation · doi-reference
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
10.1016/s0140-6736(25)01030-x · ExternalCitation · doi-reference
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
10.1038/nature21405 · ExternalCitation · doi-reference
Chromatin states define tumour-specific T cell dysfunction and reprogramming
10.1038/nature22367 · ExternalCitation · doi-reference
A human memory T cell subset with stem cell-like properties
10.1038/nm.2446 · ExternalCitation · doi-reference
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
10.1038/nm.3838 · ExternalCitation · doi-reference
CD8(+) T-cell responses to adeno-associated virus capsid in humans
10.1038/nm1549 · ExternalCitation · doi-reference
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
10.1038/nnano.2017.57 · ExternalCitation · doi-reference
The pharmacology of second-generation chimeric antigen receptors
10.1038/nrd4597 · ExternalCitation · doi-reference
Cytokine control of memory T-cell development and survival
10.1038/nri1052 · ExternalCitation · doi-reference
Molecular and cellular insights into T cell exhaustion
10.1038/nri3862 · ExternalCitation · doi-reference
Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy
10.1038/s41392-025-02512-4 · ExternalCitation · doi-reference
CAR-T cell therapy: current limitations and potential strategies
10.1038/s41408-021-00459-7 · ExternalCitation · doi-reference
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia
10.1038/s41408-021-00508-1 · ExternalCitation · doi-reference
CAR-T cells: the long and winding road to solid tumors
10.1038/s41419-018-0278-6 · ExternalCitation · doi-reference
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
10.1038/s41467-020-19486-2 · ExternalCitation · doi-reference
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics
10.1038/s41540-024-00355-3 · ExternalCitation · doi-reference
Rapid manufacturing of non-activated potent CAR T cells
10.1038/s41551-021-00842-6 · ExternalCitation · doi-reference
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing
10.1038/s41565-020-0669-6 · ExternalCitation · doi-reference
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
10.1038/s41577-020-00490-y · ExternalCitation · doi-reference
Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
10.1038/s41577-022-00825-x · ExternalCitation · doi-reference
In vivo CAR engineering for immunotherapy
10.1038/s41577-025-01174-1 · ExternalCitation · doi-reference
Lipid nanoparticles for mRNA delivery
10.1038/s41578-021-00358-0 · ExternalCitation · doi-reference
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
10.1038/s41578-022-00529-7 · ExternalCitation · doi-reference
TOX is a critical regulator of tumour-specific T cell differentiation
10.1038/s41586-019-1324-y · ExternalCitation · doi-reference
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
10.1038/s41586-019-1325-x · ExternalCitation · doi-reference
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
10.1038/s41586-019-1326-9 · ExternalCitation · doi-reference
In vivo site-specific engineering to reprogram T cells
10.1038/s41586-026-10235-x · ExternalCitation · doi-reference
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
10.1038/s41591-022-02017-5 · ExternalCitation · doi-reference
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
10.1038/s41591-026-04244-6 · ExternalCitation · doi-reference
Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors
10.1038/s43018-021-00244-2 · ExternalCitation · doi-reference
Inducible apoptosis as a safety switch for adoptive cell therapy
10.1056/nejmoa1106152 · ExternalCitation · doi-reference
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
10.1084/jem.20050732 · ExternalCitation · doi-reference
Prevalence of serum IgG and neutralizing factors against AAV types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors
10.1089/hum.2009.182 · ExternalCitation · doi-reference
Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with Sleeping Beauty transposon for the treatment of acute lymphoblastic leukemia
10.1089/hum.2017.207 · ExternalCitation · doi-reference
Quantitative systems pharmacology model of chimeric antigen receptor T-cell therapy
10.1111/cts.12636 · ExternalCitation · doi-reference
A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells
10.1126/sciadv.abf1333 · ExternalCitation · doi-reference
CAR T cells produced in vivo to treat cardiac injury
10.1126/science.abm0594 · ExternalCitation · doi-reference
In vivo CAR T cell generation to treat cancer and autoimmune disease
10.1126/science.ads8473 · ExternalCitation · doi-reference
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
10.1136/jitc-2022-006292 · ExternalCitation · doi-reference
T cell-specific non-viral DNA delivery and in vivo CAR generation using targeted lipid nanoparticles
10.1136/jitc-2025-011759 · ExternalCitation · doi-reference
Optimizing In vivo CAR-T cell engineering for cancer immunotherapy
10.1158/0008-5472.can-25-3748 · ExternalCitation · doi-reference
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells
10.1158/2326-6066.cir-14-0186 · ExternalCitation · doi-reference
Treatment with living drugs: Pharmaceutical aspects of CAR T cells
10.1159/000525052 · ExternalCitation · doi-reference
An inducible caspase 9 safety switch for T-cell therapy
10.1182/blood-2004-11-4564 · ExternalCitation · doi-reference
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
10.1182/blood-2012-05-431718 · ExternalCitation · doi-reference
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
10.1182/blood-2017-06-786129 · ExternalCitation · doi-reference
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
10.1182/blood-2017-06-793141 · ExternalCitation · doi-reference
Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010
10.1182/blood-2025-lba-1 · ExternalCitation · doi-reference
In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand
10.1182/blood.2024024523 · ExternalCitation · doi-reference
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
10.1182/bloodadvances.2020002394 · ExternalCitation · doi-reference
Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy
10.1186/s12943-025-02515-3 · ExternalCitation · doi-reference
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment
10.1186/s40164-024-00564-w · ExternalCitation · doi-reference
In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies
10.1186/s40164-025-00725-5 · ExternalCitation · doi-reference
In vivo engineering of CAR-T cells: delivery strategies and clinical translation
10.1186/s40364-026-00899-y · ExternalCitation · doi-reference
First-in-human in vivo CAR T-cell generation using a CD8-targeted lipid nanoparticle platform in relapsed/refractory B-cell lymphoma
10.1200/jco.2026.44.16_suppl.7014 · ExternalCitation · doi-reference
Dendritic cells and their role in immunotherapy
10.3389/fimmu.2020.00924 · ExternalCitation · doi-reference
Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment
10.3389/fimmu.2025.1643941 · ExternalCitation · doi-reference
T cell immunotherapy for solid tumors: limitations, progress, and future prospects
10.3389/fimmu.2026.1755751 · ExternalCitation · doi-reference
Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors
10.3389/fonc.2025.1652329 · ExternalCitation · doi-reference
Engineering the next generation of CAR T-cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance
10.3389/fonc.2025.1698442 · ExternalCitation · doi-reference
Regulatory framework for advanced therapy medicinal products in Europe and United States
10.3389/fphar.2019.00921 · ExternalCitation · doi-reference
Advancing CAR T-cell therapy in solid tumors: current landscape and future directions
10.3390/cancers17172898 · ExternalCitation · doi-reference
Eliminating REMS for CAR T-Cell Therapies: An opportunity to improve access
10.3390/cancers17193216 · ExternalCitation · doi-reference
In vivo CAR-T therapies-a new era of programmable immunity
10.3390/ijms27041737 · ExternalCitation · doi-reference
